News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Merck & Co., Inc., Ranbaxy Laboratories Drug Development Deal Called Off
January 6, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ET -- US drug maker Merck & Co has terminated its nearly two-year-old alliance with Ranbaxy Laboratories to develop anti-infective medicines , which could have fetched the Indian firm USD 100 million over a period of five years.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Asia
MORE ON THIS TOPIC
Alzheimer’s disease
Korsana Joins Alzheimer’s Amyloid Arena With $150M Debut, Next-Gen Antibody
February 18, 2026
·
2 min read
·
Tristan Manalac
Layoff Tracker
Concerto Downsizes Amid Pivot to Consumers; Faraday Closes Down
February 18, 2026
·
55 min read
·
BioSpace Editorial Staff
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
·
1 min read
·
Heather McKenzie
Opinion
Biopharma Must Cope With The Fetal Bovine Serum Squeeze
February 17, 2026
·
5 min read
·
Tom Kutrubes
